奥加伊妥珠单抗治疗成人复发或难治性CD22阳性急性淋巴细胞白血病:一项1/2期研究
这项1/2期研究评估了奥加伊妥珠单抗(InO)治疗CD22阳性复发/难治性急性淋巴细胞白血病的安全性、抗肿瘤活性、药代动力学和药效学。1期确定推荐2期剂量(RP2D)为每周期1.8 mg/m²(第1天0.8 mg/m²;第8天和第15天0.5 mg/m²),达到完全缓解(CR)或伴骨髓恢复不完全的CR(CRi)后减至每周期1.6 mg/m²。InO耐受良好,单药活性高,49例(68%)患者达CR/CRi,其中41例(84%)达微小残留病(MRD)阴性。
要点
- RP2D为每周期1.8 mg/m²,CR/CRi后减至每周期1.6 mg/m²。
- 49例(68%)达CR/CRi,其中41例(84%)达MRD阴性。
- 治疗相关毒性主要为血细胞减少,4例发生治疗相关VOD/SOS(1例致死)。
核心结论
- InO耐受良好,显示出高单药活性和MRD阴性率。
- 达到MRD阴性与较高的InO暴露相关。
研究设计与样本
- 1/2期研究,评估InO治疗CD22阳性复发/难治性急性淋巴细胞白血病的安全性、抗肿瘤活性、药代动力学和药效学。
- 1期患者接受每周期1.2 mg/m²(n=3)、1.6 mg/m²(n=12)或1.8 mg/m²(n=9),于28天周期的第1、8、15天给药(≤6周期)。
- 确认RP2D(扩展队列;n=13);在2期接受RP2D的患者(n=35)和所有接受治疗的患者(n=72)中评估安全性和活性。
主要发现
- RP2D为每周期1.8 mg/m²(第1天0.8 mg/m²;第8天和第15天0.5 mg/m²),达CR或CRi后减至每周期1.6 mg/m²。
- 治疗相关毒性主要为血细胞减少;4例发生治疗相关VOD/SOS(1例致死)。
- 2例VOD/SOS事件发生于治疗期间且未 intervening 移植;24例后续接受移植的患者中,2例移植后发生VOD/SOS。
- 49例(68%)达CR/CRi,其中41例(84%)达MRD阴性。
- 中位无进展生存期为3.9(95%CI 2.9-5.4)个月;所有治疗患者的中位总生存期为7.4(95%CI 5.7-9.2)个月,数据截止时存活患者的中位随访时间为23.7(范围6.8-29.8)个月。
关键数值与推荐
- RP2D为每周期1.8 mg/m²(第1天0.8 mg/m²;第8天和第15天0.5 mg/m²),达CR/CRi后减至每周期1.6 mg/m²。
- 49例(68%)达CR/CRi,其中41例(84%)达MRD阴性。
- 中位无进展生存期3.9(95%CI 2.9-5.4)个月;中位总生存期7.4(95%CI 5.7-9.2)个月。
- 4例发生治疗相关VOD/SOS(1例致死);2例发生于治疗期间未 intervening 移植,24例后续移植患者中2例移植后发生VOD/SOS。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of inotuzumab ozogamicin (InO) for CD22-positive relapsed/refractory acute lymphoblastic leukemia. In phase 1, patients received InO 1.2 (n = 3), 1.6 (n = 12), or 1.8 (n = 9) mg/m2 per cycle on days 1, 8, and 15 over a 28-day cycle (≤6 cycles). The recommended phase 2 dose (RP2D) was confirmed (expansion cohort; n = 13); safety and activity of InO were assessed in patients receiving the RP2D in phase 2 (n = 35) and in all treated patients (n = 72). The RP2D was 1.8 mg/m2 per cycle (0.8 mg/m2 on day 1; 0.5 mg/m2 on days 8 and 15), with reduction to 1.6 mg/m2 per cycle after complete remission (CR) or CR with incomplete marrow recovery (CRi). Treatment-related toxicities were primarily cytopenias. Four patients experienced treatment-related venoocclusive disease/sinusoidal obstruction syndrome (VOD/SOS; 1 fatal). Two VOD/SOS events occurred during treatment without intervening transplant; of 24 patients proceeding to poststudy transplant, 2 experienced VOD/SOS after transplant. Forty-nine (68%) patients had CR/CRi, with 41 (84%) achieving minimal residual disease (MRD) negativity. Median progression-free survival was 3.9 (95% confidence interval, 2.9-5.4) months; median overall survival was 7.4 (5.7-9.2) months for all treated patients, with median 23.7 (range, 6.8-29.8) months of follow-up for all treated patients alive at data cutoff. Achievement of MRD negativity was associated with higher InO exposure. InO was well tolerated and demonstrated high single-agent activity and MRD-negativity rates. This trial was registered at www.clinicaltrials.gov as #NCT01363297.
引用
- DeAngelo DJ, Stock W, Stein AS, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017. PMID: 29296758. doi:10.1182/bloodadvances.2016001925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。